EGFR and non-small cell lung carcinoma: The OPTIMAL study, a Chinese phase III randomized clinical trial (RCT), was conducted in order to compare the effectiveness of erlotinib vs. gemcitabine-carboplatine chemotherapy in NSCLC patients with epithelial growth factor receptor (EGFR) mutation.